IO Biotech, Inc.
IOBT
$0.9799
-$0.0401-3.93%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 0.33% | 4.98% | 2.77% | -1.19% | -3.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.08% | 15.26% | 22.84% | 29.55% | 28.03% |
| Operating Income | -4.08% | -15.26% | -22.84% | -29.55% | -28.03% |
| Income Before Tax | -10.34% | -13.38% | -21.35% | -25.76% | -21.44% |
| Income Tax Expenses | 69.37% | -9.08% | -65.54% | -46.59% | -33.02% |
| Earnings from Continuing Operations | -10.93% | -12.96% | -18.95% | -24.12% | -20.47% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.93% | -12.96% | -18.95% | -24.12% | -20.47% |
| EBIT | -4.08% | -15.26% | -22.84% | -29.55% | -28.03% |
| EBITDA | -4.05% | -15.28% | -22.83% | -29.49% | -27.90% |
| EPS Basic | 32.77% | 44.15% | 43.96% | 24.83% | 13.05% |
| Normalized Basic EPS | 32.88% | 43.66% | 42.72% | 23.99% | 12.68% |
| EPS Diluted | 32.77% | 44.15% | 43.96% | 24.83% | 13.05% |
| Normalized Diluted EPS | 32.88% | 43.66% | 42.72% | 23.99% | 12.68% |
| Average Basic Shares Outstanding | 51.73% | 92.90% | 115.00% | 82.84% | 50.68% |
| Average Diluted Shares Outstanding | 51.73% | 92.90% | 115.00% | 82.84% | 50.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |